PE20220488A1 - Variantes del cnp y sus conjugados - Google Patents

Variantes del cnp y sus conjugados

Info

Publication number
PE20220488A1
PE20220488A1 PE2022000426A PE2022000426A PE20220488A1 PE 20220488 A1 PE20220488 A1 PE 20220488A1 PE 2022000426 A PE2022000426 A PE 2022000426A PE 2022000426 A PE2022000426 A PE 2022000426A PE 20220488 A1 PE20220488 A1 PE 20220488A1
Authority
PE
Peru
Prior art keywords
seq
variant
group
cnp
conjugates
Prior art date
Application number
PE2022000426A
Other languages
English (en)
Inventor
Daniel J Wendt
Geoffrey Berguig
Karol Estrada
Jonathan Lebowitz
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of PE20220488A1 publication Critical patent/PE20220488A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Referida a una variante del peptido natriuretico de tipo C seleccionado del grupo que consiste en: PGQEHPQARRYRGAQRRGLSRGCFGLKLDRIGSMSGLGC (SEQ ID NO:5); PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (SEQ ID NO:1); PGQEHPNARRYRGANRRGLSRGCFGLKLDRIGSMSGLGC (SEQ ID NO:6); y PGQEHPQARKYKGAQKKGLSKGCFGLKLDRIGSMSGLGC (SEQ ID NO:7). El peptido comprende, ademas, un grupo acetilo en el extremo N-terminal y un grupo OH o un NH2 en el extremo C-terminal. Tambien esta referida a una composicion farmaceutica que comprende dicha variante. La variante es util en el tratamiento de trastornos relacionados con los huesos tales como displasias esqueleticas.
PE2022000426A 2019-09-16 2020-09-16 Variantes del cnp y sus conjugados PE20220488A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962901093P 2019-09-16 2019-09-16
US201962935050P 2019-11-13 2019-11-13
US202062963350P 2020-01-20 2020-01-20
US202062964852P 2020-01-23 2020-01-23
US202063038667P 2020-06-12 2020-06-12
PCT/US2020/051100 WO2021055497A1 (en) 2019-09-16 2020-09-16 Cnp variants and conjugates thereof

Publications (1)

Publication Number Publication Date
PE20220488A1 true PE20220488A1 (es) 2022-04-04

Family

ID=72709850

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000426A PE20220488A1 (es) 2019-09-16 2020-09-16 Variantes del cnp y sus conjugados

Country Status (15)

Country Link
US (1) US20230192799A1 (es)
EP (1) EP4031183A1 (es)
JP (1) JP2022547723A (es)
KR (1) KR20220063220A (es)
CN (1) CN114616242A (es)
AU (1) AU2020349493A1 (es)
BR (1) BR112022004697A2 (es)
CA (1) CA3153730A1 (es)
CL (1) CL2023001727A1 (es)
CO (1) CO2022004335A2 (es)
IL (1) IL291179A (es)
MX (1) MX2022003184A (es)
PE (1) PE20220488A1 (es)
TW (1) TW202124422A (es)
WO (1) WO2021055497A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023283657A1 (en) * 2021-07-09 2023-01-12 Biomarin Pharmaceutical Inc. C-type natriuretic peptide variants to treat skeletal dysplasia in children
IL313441A (en) 2021-12-07 2024-08-01 Biomarin Pharm Inc CNP therapy
CA3236278A1 (en) 2021-12-13 2023-06-22 Kennett Sprogoe Effective doses of cnp conjugates
WO2023117855A1 (en) * 2021-12-20 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of analog of c-type natriuretic peptide for the treatment of fgfr-related bone repair and bone formation impairment
WO2023227505A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
TW202419463A (zh) * 2022-11-02 2024-05-16 丹麥商諾佛 儂迪克股份有限公司 Cnp化合物
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352770A (en) 1990-04-20 1994-10-04 Hisayuki Matsuo Porcine derived novel physiologically active peptide
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
KR102225470B1 (ko) * 2009-05-20 2021-03-10 바이오마린 파머수티컬 인크. 씨형 나트륨이뇨 펩티드의 변이체
WO2017020034A1 (en) * 2015-07-30 2017-02-02 Biomarin Pharmaceutical Inc. Use of c-type natriuretic peptide variants to treat skeletal dysplasia
CA3007979C (en) * 2016-01-08 2023-12-19 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety

Also Published As

Publication number Publication date
US20230192799A1 (en) 2023-06-22
CA3153730A1 (en) 2021-03-25
AU2020349493A1 (en) 2022-04-07
BR112022004697A2 (pt) 2022-06-14
CN114616242A (zh) 2022-06-10
EP4031183A1 (en) 2022-07-27
CO2022004335A2 (es) 2022-08-30
JP2022547723A (ja) 2022-11-15
KR20220063220A (ko) 2022-05-17
CL2023001727A1 (es) 2024-01-12
IL291179A (en) 2022-05-01
TW202124422A (zh) 2021-07-01
WO2021055497A1 (en) 2021-03-25
MX2022003184A (es) 2022-06-23

Similar Documents

Publication Publication Date Title
PE20220488A1 (es) Variantes del cnp y sus conjugados
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
DOP2021000197A (es) Composición farmacéutica, que comprende la variante de hialuronidasa ph20 humana y fármaco, para inyección subcutánea
PE20120792A1 (es) Variantes de peptidos natriureticos de tipo c
MX2018001314A (es) Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica.
CL2019002132A1 (es) Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinético y sus usos.
AR072009A1 (es) Mutantes del factor de crecimiento de los fibroblastos fgf21 y usos de los mismos
HN2009001593A (es) Coagnistas de receptor de glucagon/glp-1
CO6190536A2 (es) Vacunas peptidicas para canceres que expresan antigenos asociados con tumores
ECSP056236A (es) Agonistas del receptor de la melanocortina 4 (mc4) y sus usos
PE20081140A1 (es) Agentes terapeuticos a base de peptidos derivados de toxinas
PE20200514A1 (es) Compuestos de mic-1 y usos de estos
AR072159A1 (es) Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
AR069409A1 (es) Variantes de peptidos natriureticos de tipo c
PE20091214A1 (es) Sintesis de peptidos insulinotropicos utilizando una combinacion de tecnicas en fase solida y en solucion
AR064555A1 (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo
PE20181376A1 (es) Analogos del egf(a) con sustituyentes de acidos grasos
AR096162A1 (es) Péptidos terapéuticos
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
FI3737399T3 (fi) ATF5-peptidivariantit ja niiden käytöt
ES2454773T3 (es) Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN
CL2012000715A1 (es) Compuesto agonista del receptor de peptido natriuretico b (npr-b), que comprende peptidos lineales que contienen 9 residuos aminoacidicos; y su uso para preparar un medicamento para disminuir la presion intraocular.
PE20211466A1 (es) Analogos de proteina tirosina-tirosina y metodos de uso de esta
MX2021002295A (es) Variantes de proteinas recombinantes.
PE20201254A1 (es) Analogos de compstatina y sus usos medicos